Metabolic research
Tesamorelin
Lyophilized metabolic research compound
Tesamorelin is a stabilized GHRH analog with published pharmacology and controlled-study literature on GH-axis signaling.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Mantener sellado, frío, seco y protegido de los cambios de calor. Confirme el almacenamiento específico del producto a su llegada.
Empaquetado para estabilidad en tránsito con soporte de pedidos disponible para rutas en climas cálidos.
Batch-linked certificate support is available through the documentation desk.
Contexto de investigación
Perfil de investigación de Tesamorelin
Tesamorelin is a stabilized analog of growth hormone-releasing hormone studied for its activity at the pituitary GHRH receptor. Research evaluates stimulated and pulsatile GH release, downstream IGF-1 markers, pharmacokinetics, endocrine feedback, and body-composition or metabolic endpoints in controlled settings. It differs from ghrelin-receptor secretagogues such as ipamorelin and GHRP compounds because it acts through the GHRH pathway. It also differs from shorter GHRH references such as sermorelin in sequence design and pharmacologic duration. Tesamorelin is a useful choice when a project needs a documented GHRH analog with human pharmacology literature, while keeping catalog material separate from any approved pharmaceutical product.
Mecanismo propuesto
A stabilized GHRH analog that activates the pituitary GHRH receptor, increasing cyclic AMP and stimulating pulsatile growth-hormone secretion. Downstream GH receptor signaling increases hepatic and peripheral IGF-1 production and influences lipid and carbohydrate metabolism.
Efectos reportados en estudios
- Human studies reported increased GH and IGF-1 markers and reductions in visceral adipose tissue in the populations studied.
- Controlled studies also reported changes in liver-fat, body-composition, and selected lipid markers.
- Glucose intolerance, edema, injection-site reactions, arthralgia, and elevated IGF-1 are relevant reported or monitored effects.
Criterios de investigación comunes
GHRH receptor response, GH pulse amplitude, IGF-1, visceral and liver fat, waist measures, glucose tolerance, lipids, body composition, pharmacokinetics, and adverse events.
Evidencia y limitaciones
Mechanistic and controlled human evidence exists for regulated tesamorelin products. A research catalog product is not represented as an approved or equivalent medicine.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.